Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial

Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on–and off–target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue m...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonerba, Carlo, De Placido, Pietro, Bruzzese, Dario, Pagliuca, Martina, Ungaro, Paola, Bosso, Davide, Ribera, Dario, Iaccarino, Simona, Scafuri, Luca, Liotti, Antonietta, Romeo, Valeria, Izzo, Michela, Perri, Francesco, Casale, Beniamino, Grimaldi, Giuseppe, Vitrone, Francesca, Brunetti, Arturo, Terracciano, Daniela, Marinelli, Alfredo, De Placido, Sabino, Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864863/
https://www.ncbi.nlm.nih.gov/pubmed/29615901
http://dx.doi.org/10.3389/fphar.2018.00189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864863/
https://www.ncbi.nlm.nih.gov/pubmed/29615901
http://dx.doi.org/10.3389/fphar.2018.00189

Ejemplares similares